| 2.40 Data as of May 17 |  -0.01 / -0.41%Today’s Change | 1.97 Today|||52-Week Range 8.72 | +3.00% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $150.7M |
Company Description
Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. It has received FDA approval for DUEXIS, a novel tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. The company's product portfolio comprises of DUEXIS, NP01/LODOTRA, TruNoc and HZN-602. It intends to commercialize its products in the United States to explore co-promotion opportunities for DUEXIS in the United States, and to enter into licensing or additional distribution agreements for commercialization of its products outside the United States. The company was founded on March 23, 2010 and is headquartered in Deerfield, IL.
Employees
Shareholders
| Other institutional | 29.62% |
| Individual stakeholders | 27.13% |
| Mutual fund holders | 18.06% |
Top Executives
| Timothy P. Walbert | Chairman, President & Chief Executive Officer |
| Amy Grahn | Senior VP-Clinical Development & Operations |
| Robert J. de Vaere | CFO, Executive VP & Head-Investor Relations |
| Jeffrey D. Kent, MD | Senior VP-Medical Affairs & Outcomes Research |
| Jeffrey W. Sherman, MD | Chief Medical Officer & EVP-Regulatory Affairs |
.
